De overeenkomst met Thermo Fisher Scientific biedt biowetenschappelijke onderzoekers uitgebreide massa spectrometrie oplossingen om op grote schaal diepgaande proteomische inzichten te verkrijgen

ZÜRICH–(BUSINESS WIRE)– Biognosys, een toonaangevende ontwikkelaar en leverancier van de volgende generatie proteomics-technologie en -oplossingen, en Thermo Fisher Scientific, de wereldleider in het dienen van de wetenschap met innovatieve technologieën, inkoopgemak en farmaceutische diensten, hebben vandaag aangekondigd dat ze een co-marketingovereenkomst om life science-onderzoekers te voorzien van uitgebreide massa spectrometrie oplossingen om op grote schaal diepgaande proteomics-inzichten te verkrijgen.

De overeenkomst maakt gebruik van de complementaire capaciteiten van de twee bedrijven op het gebied van op massa spectrometrie gebaseerde proteomics. Biognosys gebruikt Thermo Fisher Scientific-instrumenten in zijn ultramoderne faciliteit voor contractonderzoeksdiensten, terwijl Thermo Fisher Scientific de Biognosys-software en -kits samen met zijn Thermo Scientific™-instrumenten en -workflows op de markt brengt.

Biognosys Expands Co-Marketing Agreement with Global Life Science Leader to Advance Proteomics

The agreement with Thermo Fisher Scientific is providing life science researchers with comprehensive mass spectrometry solutions to gain deep proteomic insights at a large scale

ZURICH–(BUSINESS WIRE)– Biognosys, a leading developer and provider of next-generation proteomics technology and solutions, and Thermo Fisher Scientific, the world leader in serving science with innovative technologies, purchasing convenience and pharmaceutical services, announced today that they have extended a co-marketing agreement to provide life science researchers with comprehensive mass spectrometry solutions to gain deep proteomics insights at a large scale.

The agreement leverages the two companies’ complementary capabilities in mass spectrometry-based proteomics. Biognosys deploys Thermo Fisher Scientific instruments in its state-of-the-art facility for contract research services, while Thermo Fisher Scientific co-markets Biognosys software and kits with its Thermo Scientific™ instruments and workflows.

Biognosys’ Biomarker Discovery services for pharmaceuticals and diagnostics development integrate Thermo Scientific Orbitrap™ and FAIMS Pro™ instruments with Biognosys’ proprietary, patented Hyper Reaction Monitoring (HRM™) technology and Spectronaut™ Data Independent Acquisition (DIA) analysis software to offer unprecedented depth, quantitative precision, and throughput for unbiased discovery. This new and improved solution searches the complete proteome to quantify up to 3,000 of the most relevant proteins in biofluids and more than 10,000 proteins in tissue biopsies.

Andreas Huhmer, PhD, Senior Director Life Sciences Research OMICS Marketing at Thermo Fisher Scientific: “Biognosys’ Biomarker Discovery solutions maximize all innovative features of the Thermo Scientific Orbitrap mass spectrometers to analyze the proteome with industry-leading depth. Their unbiased discovery approach, coupled with their state-of-the-art data analysis capabilities, unlocks possibilities for transformative biomarker discovery.”

Through the companies’ extended co-marketing agreement, laboratories with in-house proteomics facilities have access to efficient, accurate, and scalable mass spectrometry-based proteomics workflows combining Thermo Scientific mass spectrometry instruments with Biognosys’ proteomics data analysis software and kits.

Lukas Reiter, PhD, Chief Technology Officer of Biognosys: “Our agreement with Thermo Fisher Scientific has helped to greatly advance Biognosys’ mission to give researchers a look at every angle of the proteome to unlock discoveries and transform clinical research. Our suite of software and kits uniquely complements Thermo Scientific mass spectrometry instruments and workflows to enable researchers to obtain the best possible data and insights in any proteomics application.”

Biognosys’ leading DIA software solution, Spectronaut, is compatible with Thermo Scientific Orbitrap Exploris™ 480 and Thermo Scientific™ Q Exactive™ instruments.

Biognosys’ SpectroDive™ software for automated mass spectrometry method set-up, signal processing, and analysis of targeted proteomics experiments supports the SureQuant IS-PRM targeted acquisition workflow.

The PQ500™ Reference Peptide Kit from Biognosys can quantify more than 500 proteins in human plasma/serum samples as part of the SureQuant IS-PRM workflow with the Orbitrap Exploris™ 480 mass spectrometer, delivering sensitive and accurate quantitation to drive scientific progress or clinical decision making.

Learn more about the insights that can be uncovered through the Biognosys and Thermo Fisher Scientific partnership from Lukas Reiter’s presentation, “Recent Progress in Blood Proteomics”, during the Thermo Fisher Scientific dinner workshop at ASMS 2021.

About Biognosys

Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005070/en/

Contacts

Media Contact
Yves Serroen
Head of Marketing

Phone +41 (0) 79 571 09 21

yves.serroen@biognosys.com